GPR35 activation reduces Ca2+ transients and contributes to the kynurenic acid-dependent reduction of synaptic activity at CA3-CA1 synapses

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Berlinguer Palmini, Rolando ^a   Masi, Alessio ^a   Narducci, Roberto ^a   Cavone, Leonardo ^a   Maratea, Dario ^a   Cozzi, Andrea ^a   Sili, Maria ^a   Moroni, Flavio ^a   Mannaioni, Guido ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BUNGAROTOXIN RECEPTOR; CALCIUM ION; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 35; KYNURENIC ACID; N METHYL DEXTRO ASPARTIC ACID; PHOSPHODIESTERASE V; UNCLASSIFIED DRUG; ZAPRINAST;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTE CULTURE; CALCIUM TRANSPORT; CELL ACTIVATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; INTRACELLULAR TRANSPORT; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; RAT; SYNAPSE; SYNAPTIC TRANSMISSION;

ANIMALS; ASTROCYTES; BASE SEQUENCE; CALCIUM; CELLS, CULTURED; DNA PRIMERS; HIPPOCAMPUS; KYNURENIC ACID; MICE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, G-PROTEIN-COUPLED; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 84896700631     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082180     Document Type: Article

References (54)

1. O'Dowd BF, Nguyen T, Marchese A, Cheng R, Lynch KR et al. (1998) Discovery of three novel G-protein-coupled receptor genes. Genomics 47: 310-313. doi:10.1006/geno.1998.5095. PubMed: 9479505. (Pubitemid 28086858)
2. Jenkins L, Brea J, Smith NJ, Hudson BD, Reilly G et al. (2010) Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of ß-arrestin-2 and activate Gα13. Biochem J 432: 451-459. doi:10.1042/BJ20101287. PubMed: 20919992.
3. Ohshiro H, Tonai-Kachi H, Ichikawa K (2008) GPR35 is a functional receptor in rat dorsal root ganglion neurons. Biochem Biophys Res Commun 365: 344-348. doi:10.1016/j.bbrc.2007.10.197. PubMed: 17996730. (Pubitemid 350137295)
4. Taniguchi Y, Tonai-Kachi H, Shinjo K (2006) Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett 580: 5003-5008. doi:10.1016/j.febslet.2006.08.015. PubMed: 16934253. (Pubitemid 44332369)
5. Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J et al. (2006) Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 281: 22021-22028. doi:10.1074/jbc.M603503200. PubMed: 16754668. (Pubitemid 44181906)
6. Moroni F, Cozzi A, Sili M, Mannaioni G (2012) Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm 119: 133-139. doi:10.1007/s00702-011-0763-x. PubMed: 22215208.
7. Stone TW, Stoy N, Darlington LG (2013) An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol Sci 34: 136-143. doi:10.1016/j.tips.2012.09.006. PubMed: 23123095.
8. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA et al. (2001) Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50: 521-530. doi:10.1016/S0006-3223(01)01078-2. PubMed: 11600105. (Pubitemid 32971883)
9. Erhardt S, Blennow K, Nordin C, Skogh E, Lindström LH et al. (2001) Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 313: 96-98. doi:10.1016/S0304-3940(01)02242-X. PubMed: 11684348. (Pubitemid 32973903)
10. Carpenedo R, Meli E, Peruginelli F, Pellegrini-Giampietro DE, Moroni F (2002) Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in organotypic hippocampal slice cultures. J Neurochem 82: 1465-1471. doi:10.1046/j.1471-4159.2002.01090.x. PubMed: 12354294.
11. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ (2012) Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 13: 465-477. doi:10.1038/nrn3257. PubMed: 22678511.
12. Oka S, Ota R, Shima M, Yamashita A, Sugiura T (2010) GPR35 is a novel lysophosphatidic acid receptor. Biochem Biophys Res Commun 395: 232-237. doi:10.1016/j.bbrc.2010.03.169. PubMed: 20361937.
13. Jenkins L, Alvarez-Curto E, Campbell K, de Munnik S, Canals M et al. (2011) Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Galpha and beta-arrestin-2. Br J Pharmacol 162: 733-748. doi:10.1111/j.1476-5381.2010.01082.x. PubMed: 20958291.
14. Zhao P, Sharir H, Kapur A, Cowan A, Geller EB et al. (2010) Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol 78: 560-568. doi:10.1124/mol.110.066746. PubMed: 20826425.
15. Yang Y, Lu JY, Wu X, Summer S, Whoriskey J et al. (2010) G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium. Pharmacology 86: 1-5. doi: 10.1159/000314164. PubMed: 20559017.
16. Deng H, Hu H, He M, Hu J, Niu W et al. (2011) Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2- carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists. J Med Chem 54: 7385-7396. doi:10.1021/jm200999f. PubMed: 21950657.
17. Deng H, Hu H, Fang Y (2011) Tyrphostin analogs are GPR35 agonists. FEBS Lett 585: 1957-1962. doi:10.1016/j.febslet.2011.05.026. PubMed: 21601572.
18. Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45: 309-379. PubMed: 8248282.
19. Hilmas C, Pereira EFR, Alkondon M, Rassoulpour A, Schwarcz R et al. (2001) The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non α7 nicotinic receptor expression: physiopathological implications. J Neurosci 21: 7463-7473. PubMed: 11567036. (Pubitemid 32904945)
20. Carpenedo R, Pittaluga A, Cozzi A, Attucci S, Galli A et al. (2001) Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur J Neurosci 13: 2141-2147. doi:10.1046/j.0953-816x.2001.01592.x. PubMed: 11422455. (Pubitemid 32578800)
21. Cosi C, Mannaioni G, Cozzi A, Carlà V, Sili M et al. (2011) G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast. Neuropharmacology 60: 1227-1231. PubMed: 21110987.
22. Wu ML, Chen WH, Liu IH, Tseng CD, Wang SM (1999) A novel effect of cyclic AMP on capacitative Ca2+ entry in cultured rat cerebellar astrocytes. J Neurochem 73: 1318-1328. PubMed: 10461927.
23. Lee CJ, Mannaioni G, Yuan H, Woo DH, Gingrich MB et al. (2007) Astrocytic control of synaptic NMDA receptors. J Physiol 581: 1057-1081. doi:10.1113/jphysiol.2007.130377. PubMed: 17412766. (Pubitemid 46887980)
24. Vellani V, Zachrisson O, McNaughton PA (2004) Functional bradykinin B1 receptors are expressed in nociceptive neurones and are upregulated by the neurotrophin GDNF. J Physiol 560: 391-401. doi: 10.1113/jphysiol.2004.067462. PubMed: 15319421. (Pubitemid 39440102)
25. Luo D, Broad LM, Bird GS, Putney JWJ (2001) Signaling pathways underlying muscarinic receptor-induced [Ca2+]i oscillations in HEK293 cells. J Biol Chem 276: 5613-5621. doi:10.1074/jbc.M007524200. PubMed: 11096083.
26. Takemura H, Hughes AR, Thastrup O, Putney JWJ (1989) Activation of calcium entry by the tumor promoter thapsigargin in parotid acinar cells. Evidence that an intracellular calcium pool and not an inositol phosphate regulates calcium fluxes at the plasma membrane. J Biol Chem 264: 12266-12271. PubMed: 2663854. (Pubitemid 19191112)
27. Mannaioni G, Marino MJ, Valenti O, Traynelis SF, Conn PJ (2001) Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J Neurosci 21: 5925-5934. PubMed: 11487615. (Pubitemid 32737725)
28. Masi A, Narducci R, Landucci E, Moroni F, Mannaioni G (2013) MPP(+) -dependent inhibition of I(h) reduces spontaneous activity and enhances EPSP summation in nigral dopamine neurons. Br J Pharmacol Epub ahead of print.
29. Cosi C, Mannaioni G, Cozzi A, Carlà V, Sili M et al. (2011) G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast. Neuropharmacology 60: 1227-1231. doi:10.1016/j.neuropharm.2010.11.014. PubMed: 21110987.
30. Cozzi A, Attucci S, Peruginelli F, Marinozzi M, Pellicciari R et al. (1997) Type 2 metabotropic glutamate receptors (mGluRs) tonically inhibit transmitter release in rat caudate nucleus: in vivo studies with (2S,1S, 2S,3R)-2-(2-Carboxy-3-phenylcyclopropyl)glycine (PCCG-IV), a new potent and selective antagonist. Eur J Neurosci 9: 1350-1355. doi: 10.1111/j.1460-9568. 1997.tb01489.x. PubMed: 9240392.
31. Lombardi G, Alesiani M, Leonardi P, Cherici G, Pellicciari R et al. (1993) Pharmacological characterization of the metabotropic glutamate receptor inhibiting D- 3H-aspartate output in rat striatum. Br J Pharmacol 110: 1407-1412. doi:10.1111/j.1476-5381.1993.tb13977.x. PubMed: 8306080. (Pubitemid 23360970)
32. Verkhratsky A, Kettenmann H (1996) Calcium signalling in glial cells. Trends Neurosci 19: 346-352. doi:10.1016/0166-2236(96)10048-5. PubMed: 8843604. (Pubitemid 26349064)
33. Zaccolo M, Pozzan T (2003) cAMP and Ca2+ interplay: a matter of oscillation patterns. Trends Neurosci 26: 53-55. doi:10.1016/S0166-2236(02) 00017-6. PubMed: 12536124. (Pubitemid 36110535)
34. Lefkimmiatis K, Srikanthan M, Maiellaro I, Moyer MP, Curci S et al. (2009) Store-operated cyclic AMP signalling mediated by STIM1. Nat Cell Biol 11: 433-442. doi:10.1038/ncb1850. PubMed: 19287379.
35. Banerjee J, Alkondon M, Albuquerque EX (2012) Kynurenic acid inhibits glutamatergic transmission to CA1 pyramidal neurons via α7 nAChR-dependent and -independent mechanisms. Biochem Pharmacol 84: 1078-1087. doi:10.1016/j.bcp.2012.07.030. PubMed: 22889930.
36. Mok MHS, Fricker ACF, Weil A, Kew JN (2009) Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels. Neuropharmacology 57: 242-249. doi:10.1016/j.neuropharm.2009.06.003. PubMed: 19523966.
37. Boulton CL, Irving AJ, Southam E, Potier B, Garthwaite J et al. (1994) The nitric oxide-cyclic GMP pathway and synaptic depression in rat hippocampal slices. Eur J Neurosci 6: 1528-1535. doi:10.1111/j.1460-9568.1994.tb00543.x. PubMed: 7850017. (Pubitemid 24310360)
38. Broome MR, Collingridge GL, Irving AJ (1994) Activation of the NOcGMP signalling pathway depresses hippocampal synaptic transmission through an adenosine receptor-dependent mechanism. Neuropharmacology 33: 1511-1513. doi: 10.1016/0028-3908(94)90056-6. PubMed: 7870292. (Pubitemid 24353748)
39. Moroni F, Russi P, Gallo-Mezo MA, Moneti G, Pellicciari R (1991) Modulation of quinolinic and kynurenic acid content in the rat brain: effects of endotoxins and nicotinylalanine. J Neurochem 57: 1630-1635. doi:10.1111/j.1471-4159.1991.tb06361.x. PubMed: 1833509. (Pubitemid 21922799)
40. Carpenedo R, Chiarugi A, Russi P, Lombardi G, Carlà V et al. (1994) Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenic acid and have sedative and anticonvulsant activities. Neuroscience 61: 237-244. doi: 10.1016/0306-4522(94)90227-5. PubMed: 7969905. (Pubitemid 24219003)
41. Vécsei L, Beal MF (1991) Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats. Eur J Pharmacol 196: 239-246. doi:10.1016/0014-2999(91)90436-T. PubMed: 1893912.
42. Németh H, Robotka H, Kis Z, Rózsa E, Janáky T et al. (2004) Kynurenine administered together with probenecid markedly inhibits pentylenetetrazol-induced seizures. An electrophysiological and behavioural study. Neuropharmacology 47: 916-925. doi:10.1016/j.neuropharm.2004.06.007. PubMed: 15527825. (Pubitemid 39440985)
43. Cozzi A, Carpenedo R, Moroni F (1999) Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (RO 61-8048) in models of focal or global ischemia. J Cereb Blood Flow Metab 19: 771-777. PubMed: 10413032. (Pubitemid 30159803)
44. Chiarugi A, Carpenedo R, Moroni F (1996) Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase. J Neurochem 69: 692-698. PubMed: 8764597. (Pubitemid 26255666)
45. Nozaki K, Beal MF (1992) Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. J Cereb Blood Flow Metab 12: 400-407. doi:10.1038/jcbfm.1992.57. PubMed: 1569135.
46. Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P et al. (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145: 863-874. doi:10.1016/j.cell. 2011.05.020. PubMed: 21640374.
47. Campesan S, Green EW, Breda C, Sathyasaikumar KV, Muchowski PJ et al. (2011) The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr Biol 21: 961-966. doi: 10.1016/j.cub.2011.04.028. PubMed: 21636279.
48. Guidetti P, Hoffman GE, Melendez-Ferro M, Albuquerque EX, Schwarcz R (2007) Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia 55: 78-92. doi:10.1002/glia.20432. PubMed: 17024659. (Pubitemid 44845511)
49. Potter MC, Elmer GI, Bergeron R, Albuquerque EX, Guidetti P et al. (2010) Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 35: 1734-1742. PubMed: 20336058.
50. Zaccolo M, Pozzan T (2003) cAMP and Ca2+ interplay: a matter of oscillation patterns. Trends Neurosci 26: 53-55. doi:10.1016/S0166-2236(02) 00017-6. PubMed: 12536124. (Pubitemid 36110535)
51. Willoughby D (2012) Organization of cAMP signalling microdomains for optimal regulation by Ca2+ entry. Biochem Soc Trans 40: 246-250. doi: 10.1042/BST20110613. PubMed: 22260699.
52. Guo J, Williams DJ, Puhl HL3, Ikeda SR (2008) Inhibition of N-type calcium channels by activation of GPR35, an orphan receptor, heterologously expressed in rat sympathetic neurons. J Pharmacol Exp Ther 324: 342-351. (Pubitemid 350294182)
53. Reyes RC, Parpura V (2009) The trinity of Ca2+ sources for the exocytotic glutamate release from astrocytes. Neurochem Int 55: 2-8. doi:10.1016/j.neuint. 2008.12.018. PubMed: 19171170.
54. Perea G, Araque A (2007) Astrocytes potentiate transmitter release at single hippocampal synapses. Science 317: 1083-1086. doi:10.1126/science. 1144640. PubMed: 17717185. (Pubitemid 47330192)